Meyer TD
Louis A. Faillace, MD, Department of Psychiatry & Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA Thomas.d.meyer@uth.tmc.edu.
ArticlePsilocybin
Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study.
ArticlePsilocybin
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
ArticlePsilocybin
Contemplating versus having used psychedelics in bipolar disorder - What makes the difference?
ArticlePsilocybin
Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].
PreprintPsychedelics
Commentary on methods for addressing functional unblinding and mechanistic uncertainty in clinical trials of psychedelic-assisted treatments
PreprintPsychedelics
Commentary on methods for addressing functional unblinding and mechanistic uncertainty in clinical trials of psychedelic-assisted treatments
ArticlePsilocybin
The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
ArticlePsilocybin
Psychedelic use and bipolar disorder - An investigation of recreational use and its impact on mental health.
ArticlePsilocybin
Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?
ArticlePsilocybin
Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment.
ArticlePsilocybin